Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.
Attia D, El Saeed K, Elakel W, El Baz T, Omar A, Yosry A, Elsayed MH, Said M, El Raziky M, Anees M, Doss W, El Shazly Y, Wedemeyer H, Esmat G. Attia D, et al. Among authors: el baz t, el saeed k, el raziky m, el shazly y. Aliment Pharmacol Ther. 2018 May;47(9):1296-1305. doi: 10.1111/apt.14538. Epub 2018 Mar 5. Aliment Pharmacol Ther. 2018. PMID: 29504152
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhlouf MA, Waked I, Abdelaziz AO, Yosry A, El Serafy M, Thursz M, Doss W, Esmat G. Elsharkawy A, et al. Among authors: el serafy m, el demerdash t, el raziky m, el akel w, el shazly y. Aliment Pharmacol Ther. 2017 Mar;45(5):681-687. doi: 10.1111/apt.13923. Epub 2017 Jan 9. Aliment Pharmacol Ther. 2017. PMID: 28070899
Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.
Esmat G, El Akel W, Metwally M, Soliman A, Doss W, Hamid MA, Kamal M, Zalata K, Khattab H, El-Kassas M, Esmat M, Hasan A, El-Raziky M. Esmat G, et al. Among authors: el kassas m, el raziky m, el akel w. Indian J Gastroenterol. 2009 Mar-Apr;28(2):45-8. doi: 10.1007/s12664-009-0016-1. Epub 2009 Aug 21. Indian J Gastroenterol. 2009. PMID: 19696987
The future for the treatment of genotype 4 chronic hepatitis C.
Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. Esmat G, et al. Among authors: el kassas m, el raziky m. Liver Int. 2012 Feb;32 Suppl 1:146-50. doi: 10.1111/j.1478-3231.2011.02704.x. Liver Int. 2012. PMID: 22212586 Review.
Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
El Raziky M, Gamil M, Ashour MK, Sameea EA, Doss W, Hamada Y, Van Dooren G, DeMasi R, Keim S, Lonjon-Domanec I, Hammad R, Hashim MS, Hassany M, Waked I. El Raziky M, et al. J Viral Hepat. 2017 Feb;24(2):102-110. doi: 10.1111/jvh.12625. Epub 2016 Oct 27. J Viral Hepat. 2017. PMID: 27790789 Clinical Trial.
Hepatitis C virus infection in Egyptian children: single centre experience.
El-Raziky MS, El-Hawary M, El-Koofy N, Okasha S, Kotb M, Salama K, Esmat G, El-Raziky M, Abouzied AM, El-Karaksy H. El-Raziky MS, et al. Among authors: el hawary m, el karaksy h, el koofy n, el raziky m. J Viral Hepat. 2004 Sep;11(5):471-6. doi: 10.1111/j.1365-2893.2004.00535.x. J Viral Hepat. 2004. PMID: 15357655
How to optimize HCV therapy in genotype 4 patients.
Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. Esmat G, et al. Among authors: el kassas m, el raziky m. Liver Int. 2013 Feb;33 Suppl 1:41-5. doi: 10.1111/liv.12059. Liver Int. 2013. PMID: 23286845 Review.
88 results